Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | PNMT | P11086 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23258737 | 0.94 | HRH3 (0.61) | HRH3ADRA2AADRA2BADRA2CHRH1 | |
| SCHEMBL22755555 | 0.87 | HRH3 (0.46) | HRH3HRH1CD274 | |
| SCHEMBL30101456 | 0.87 | HRH3 (0.46) | HRH3HRH1CD274 | |
| SCHEMBL12895388 | 0.84 | HRH3 (0.61) | HRH3ADRA2AADRA2BADRA2CHRH1 | |
| Hydrochloric Acid SCHEMBL1266623 | 0.83 | HRH3 (0.60) | HRH3ADRA2AADRA2BADRA2CHRH1 | |
| SCHEMBL21659430 | 0.83 | HRH3 (0.60) | HRH3ADRA2AADRA2BADRA2CHRH1 | |
| Hydrochloric Acid SCHEMBL4715868 | 0.82 | HRH3 (0.59) | HRH3ADRA2AADRA2BADRA2CHRH1 | |
| Hydrochloric Acid SCHEMBL31014010 | 0.80 | HRH3 (0.71) | HRH3ADRA2AADRA2BADRA2CHRH1 | |
| SCHEMBL23321027 | 0.79 | ALOX15 (0.66) | HRH3ADRA2AADRA2BADRA2CPNMT | |
| SCHEMBL30778174 | 0.78 | TSHR (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459323-B2 | Monocyclic β-lactam compound for treating bacterial infection | MEDSHINE DISCOVERY INC. (CN) | 2022-10-04 | — | — | US | disclosed |
| US-20210115035-A1 | MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION | Shenzhen Optimum Biological Technology Co., Ltd (CN) | 2021-04-22 | — | — | US | disclosed |
| EP-3747883-A1 | MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION | Medshine Discovery Inc. (CN) | 2020-12-09 | — | — | EP | disclosed |
| EP-1940819-A1 | PHOSPHODIESTERASE 10 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007022280-A1 | PHOSPHODIESTERASE 10 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE12, PDE10A | HRH3 4640/4885ADRA2A 1301/4885ADRA2B 1507/4885 |
| US-11459323-B2 | Monocyclic β-lactam compound for treating bacterial infection | PEPD, COASY, MRPL21 | HRH3 2491/4885ADRA2A 1440/4885ADRA2B 1291/4885 |
| US-20210115035-A1 | MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION | COASY, BCAT2, PEPD | HRH3 2159/4885ADRA2A 1669/4885ADRA2B 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.